Is non-pharmacological treatment an option for certain schizophrenia patients?

Schizophrenia treatment has been debated at length and presently pharmacological treatment is being advocated as the most beneficial for patients. However, research has shown contradictory results regarding the suitability of pharmacological treatment for certain groups of schizophrenia patients.

The present review discusses results from the literature indicating good outcomes only for patients who adhered to prescribed pharmacological treatments. It also describes studies favoring non-drug treatments in certain schizophrenic patients.

The authors described two groups of patients where the long-term use of neuroleptics may be useless, if not harmful. The first group comprised schizophrenic people with a single psychotic episode and therefore very good prognosis. In their case, the prolonged use of antipsychotics would not be beneficial due to pharmacological and social (stigma) side effects. Further research is warranted to identify and investigate biological, environmental, and psychological factors associated with single-episode schizophrenia. The second group comprised ultra-resistant schizophrenic patients. In their case, in the absence of a therapeutic response in acute episodes or aggressive behavior, clinicians should use short episodes of treatment with benzodiazepines or other sedative medications such as mood stabilizers.

The present paper attempted to answer the important question as to whether all schizophrenic people should be treated with antipsychotics for the same good prognosis. The authors have provided solutions for better outcomes in a greater number of patients using alternative treatment after identifying schizophrenic patients who should not receive neuroleptic treatment. Suggestions for future research are also discussed.